Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia 9Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Burkitt Lymphoma 6Recurrence 5Lymphoma, Follicular 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Biphenotypic, Acute 4Sezary Syndrome 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Blast Crisis 3Waldenstrom Macroglobulinemia 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell 2Lymphoma, AIDS-Related 2Leukemia, Myelomonocytic, Chronic 2

Interventions

Doxorubicin 2tazemetostat 1romidepsin 1pembrolizumab 1etoposide phosphate 1duvelisib 1cc-486 1Vincristine 1Prednisone 1Prednisolone 1Melphalan 1Etoposide 1Cytarabine 1Cyclophosphamide 1Carmustine 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Enteropathy-Associated T-Cell Lymphoma × Cytarabine × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡